−9.8403USD
−14.47 MUSD
19.59 MUSD
6.59 M
About Agile Therapeutics, Inc.
Sector
CEO
Alfred F. Altomari
Headquarters
Princeton
Website
Employees (FY)
19
Founded
1997
ISIN
US00847L3087
FIGI
BBG00660K284
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AGRX is 0.3800 USD — it has increased by 2.70% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Agile Therapeutics, Inc. stocks are traded under the ticker AGRX.
Agile Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
AGRX stock is 7.34% volatile and has beta coefficient of 1.14. Check out the list of the most volatile stocks — is Agile Therapeutics, Inc. there?
AGRX earnings for the last quarter are −1.47 USD per share, whereas the estimation was −1.84 USD resulting in a 20.11% surprise. The estimated earnings for the next quarter are −0.92 USD per share. See more details about Agile Therapeutics, Inc. earnings.
Agile Therapeutics, Inc. revenue for the last quarter amounts to 6.66 M USD despite the estimated figure of 6.77 M USD. In the next quarter revenue is expected to reach 4.07 M USD.
Yes, you can track Agile Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
AGRX stock has fallen by 2.66% compared to the previous week, the month change is a 28.37% fall, over the last year Agile Therapeutics, Inc. has showed a 94.30% decrease.
AGRX net income for the last quarter is −4.47 M USD, while the quarter before that showed −799.00 K USD of net income which accounts for −459.07% change. Track more Agile Therapeutics, Inc. financial stats to get the full picture.
Today Agile Therapeutics, Inc. has the market capitalization of 2.54 M, it has increased by 44.53% over the last week.
No, AGRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AGRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Agile Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 19.00 employees. See our rating of the largest employees — is Agile Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Agile Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Agile Therapeutics, Inc. stock shows the sell signal. See more of Agile Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Agile Therapeutics, Inc. EBITDA is −19.50 M USD, and current EBITDA margin is −99.52%. See more stats in Agile Therapeutics, Inc. financial statements.